As of July 29, 2026, the clinical trial NCT05946798, titled "Role of NADPH Oxidase in Microvascular Dysfunction Following GDM," has updated its status to active, not recruiting. The trial involves insulin aspart, an approved insulin analog. This is an Early Phase 1 study, indicating an initial stage of clinical investigation.
The status "active, not recruiting" means the trial is ongoing but is no longer enrolling new participants. No results or outcome data have been reported as part of this status update. This brief reflects only the trial's current phase and recruitment status as listed on ClinicalTrials.gov.
Readers interested in the study details, including its design and objectives, can consult the official trial registration. No efficacy or safety conclusions can be drawn from a status update alone. Further updates may be issued as the trial progresses toward completion or results reporting.
For more background on insulin aspart, including its approved uses and general profile, see the compound overview.